WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - April 07, 2016) - Clinical Ink®, the pioneering provider of eSource solutions for clinical trials, today announced that Scott Miltenberger has joined the company as Chief Financial Officer (CFO). As Chief Financial Officer, Scott Miltenberger leads Clinical Ink's accounting, business planning and global financial operations. He reports directly to Clinical Ink CEO, Ed Seguine.

"It's a privilege to join Clinical Ink, a company that brings together a unique mix of entrepreneurial talent and seasoned, global expertise," said Scott. "The dynamic and fast-moving environment is exciting, and I look forward to working with this team to help develop and support clinical trial sponsors and partner companies in their innovative, and potentially industry-transforming, work."

Mr. Miltenberger brings more than 20 years of financial management and technology industry experience, primarily in executive roles leading strategic global financial operations. Prior to joining Clinical Ink, Mr. Miltenberger was Chief Financial Officer for Evolve IP through GPX Enterprises, a private equity firm focused on the sponsorship, development and management of selected investments, where he helped lead the company through a period of rapid growth. Prior to Evolve IP, Scott served as CFO for Elemica, a cloud-based software services company, where he led the company's financial strategy, capital raising initiatives, and was instrumental in the organization's M&A activities. Scott began his career at Deloitte & Touche LLP.

"Scott comes to us with a superb track record at high-tech, high-growth companies, and he will be a tremendous asset to our management team during Clinical Ink's growth and maturation," said Ed Seguine, Chief Executive Officer of Clinical Ink. "I am confident that he will enhance our ability to transform clinical trials through novel technology and process innovation. We are delighted to have him on the Clinical Ink team."

Capturing patient data electronically in real-time using Clinical Ink's SureSource at clinical trial sites and CentrosHealth for patients, ensures the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission, and delivers benefits that legacy technologies do not. Clinical Ink eliminates the need for EDC and on-site source data verification, allowing for true remote monitoring saving time and money while increasing quality.

About Clinical Ink

Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier -- for sites, sponsors and patients. Clinical Ink's SureSource® and CentrosHealth® solutions directly capture eSource data and documents and improve patient engagement while streamlining clinical development. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA. Find more at

Contact Information:

Jim Dorsey
Clinical Ink